Radioligand therapies such as [177Lu] Lu-PSMA-617 have gained significant momentum in cancer treatment after clinical trials and multicenter studies demonstrated their safety and efficacy. As these innovative treatments become more widespread, rare and unique clinical manifestations are expected to be observed. In this report, we describe a case with metastatic castration-resistant prostate cancer (mCRPC) and peripancreatic lymph node metastases who developed acute pancreatitis following [177Lu] Lu-PSMA-617 therapy.
Frontiers in oncology. 2024 Oct 07*** epublish ***
Gokce Belge Bilgin, Patrick J Navin, Derek R Johnson, Oliver Sartor, Ayse Tuba Kendi
Department of Radiology, Mayo Clinic, Rochester, MN, United States.